Siegfried delivers strong sales growth and profitability in first half 2023
We aim to strengthen Siegfried‘s standing and credibility with the public and enhance long-term enterprise value. As our focus is on transparency, we disclose all relevant information to facilitate a comprehensive assessment of our company.
at a Glance
As a worldwide leading contract and development manufacturing organization, we produce pharmaceutical ingredients and finished products as an integrated supplier.
The Siegfried Group is a global life sciences company with a network of 11 sites in Europe, the USA and Asia. We provide integrated contract development and manufacturing services for the pharmaceutical industry.
Siegfried supplies approximately 200 out of 1500 APIs approved by the FDA. We serve more than 500 customers globally, and up to one billion people get in contact with Siegfried products every year. Over 100 million doses of Covid-19 vaccines have been manufactured by Siegfried.
Siegfried offers contract developing and manufacturing of active pharmaceutical ingredients, intermediates and finished dosage forms. Our integrated approach ensures that we can provide a range of services, from process development and optimization to registration, production, packaging and logistics.
With our expertise in process optimization, we help our customers to develop greener production processes, which require less energy and produce less waste while maximizing the safety of our products. Siegfried is a member of the Dow Jones Sustainability Index Europe and rated AA by MSCI.
Founded in 1873 by pharmacist Samuel Benoni Siegfried in Zofingen, Switzerland, the company has been growing steadily ever since. Siegfried evolved into a global player with state-of-the-art facilities and cutting-edge technologies through the strategic acquisition of three sites from BASF in 2015 and two Spanish sites from Novartis in 2021.